Eton Q4 2022: product revenue +220% YoY, net income positive; CEO sees 2023 doubling

Eton Pharmaceuticals, Inc.

Q4 net revenue $8.5M (incl. $5M milestone); product/royalty $3.5M (+220% YoY, +9% QoQ).
Net income $0.9M ($0.04 diluted EPS); gross profit $6.4M; cash $16.3M at Dec 31, 2022.
Eighth straight sequential product revenue growth; CEO expects at least 2x product/royalty revenue in 2023.
Expanded rare disease sales force to 12 specialists; Betaine launch imminent; Dehydrated Alcohol NDA action date June 27, 2023.
Acquired ET-600 (rare pediatric endocrinology); ET-400 NDA expected by end of 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Eton Pharmaceuticals, Inc. reported financial results for fourth quarter ended December 31, 2022.

Period: fourth quarter ended December 31, 2022
Result: reported results

Exact text from the filing

Net income for the fourth quarter of 2022 was $0.9 million or $0.04 per basic and diluted share compared to a net income of $1.0 million or $0.04 per diluted share in the prior year period

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Eton Pharmaceuticals, Inc. reported fourth quarter and year ended December 31, 2022 results: revenue $8.5 million, net income $0.9 million, EPS $0.04 per basic and diluted share.

Period: fourth quarter and year ended December 31, 2022
Revenue: $8.5 million
Net income: $0.9 million
EPS: $0.04 per basic and diluted share
Result: reported results

Exact text from the filing

Net revenues for the fourth quarter of 2022 were $8.5 million compared with $6.1 million in the prior year period

View on SEC.gov

Browse all earnings releases →

Eton Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-007916

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.